Bufalin, a key active ingredient of the Chinese medicine Chan Su, inhibits breast cancer tumorigenesis in vitro and in vivo. Here, we found that the pan-caspase inhibitor zVAD-fmk failed to inhibit bufalin-induced cell death in MCF-7 and MDA-MB-231 human breast cancer cells, confirming that the cell death induced by bufalin is caspase-independent. Instead, bufalin increased the expression of the necroptosis mediators RIP1 and RIP3. Bufalin-induced cell death was prevented by small molecule inhibitors of RIP1 and poly (ADP-ribose) polymerase-1 (PARP-1) or genetic knockdown of RIP3 by shRNA transfection. In addition, ectopic RIP3 expression enhanced cell death by bufalin. We also found that bufalin increased intracellular reactive oxygen species levels; and cell death by bufalin was inhibited by the antioxidant NAC. In a mouse xenograft model of human breast cancer, bufalin induced PARP-1-dependent tumor cell death and inhibited tumor growth. These results demonstrated that bufalin inhibits human breast cancer tumorigenesis by inducing cell death through the reactive oxygen species-mediated RIP1/RIP3/PARP-1 pathways.
Introduction
Necrosis and apoptosis are two major forms of cell death. Classically, necrosis is thought to be an unregulated digestion of cell components, and apoptosis, a programmed process that is promoted by caspases. Deregulation of apoptotic pathways often contributes to cancer development. Many anticancer drugs trigger apoptosis to eliminate malignant cells (1) . However, activation of antiapoptotic and/or survival pathways in cancer cells often leads to therapeutic resistance. Thus, finding pharmaceutical interventions that target alternative cell death pathways is a new focus in cancer therapy (2) .
Although necrosis is generally thought to be an 'unprogrammed' cell death process, recent studies have found evidence that it can also occur through a programmed mechanism termed necroptosis or programmed necrosis (3) . Necroptosis can be triggered by reactive oxygen species (ROS), cytokines, alkylating DNA damage or irradiation and is executed through unique signaling pathways: the receptor interacting protein (RIP)1/RIP3-dependent pathway activated by extracellular stimuli such as tumor necrosis factor (TNF) and/or the poly(ADPribose) polymerase-1 (PARP-1) pathway triggered by continued DNA damage (4) . PARP-1 can also act as a downstream effector of RIP/RIP3 in necroptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) (5) . Unlike apoptosis, necroptosis is not mediated by caspases, but can be blocked by necrostatin-1 (Nec-1), a specific small molecule inhibitor of RIP1 (6) . Although the biochemical basis of necroptosis has just begun to emerge, there is an increasing evidence demonstrating that genetic or epigenetic deregulation of necroptotic regulators occurs in cancer and is associated with clinical outcome of patients (7) . For example, RIP3 is downregulated in breast and colorectal cancer, and lower RIP3 levels are correlated with disease progression and poor survival (8, 9) . Restoration or ectopic expression of RIP3 can sensitize a range of cancer cell lines to chemotherapeutic agents that cause DNA damages (8) . Evidence also shows that necroptosis is activated in response to many anticancer drugs and contributes to their antitumor effects. These findings support therapeutic exploitation of necroptosis as a new approach for cancer therapy (10) .
Bufalin is a digoxin-like active ingredient of Chan Su, a traditional Chinese medicine prepared from the skin and parotid venom glands of toads (11) . Bufalin exhibits in vitro and in vivo antitumor activities in a wide spectrum of cancer (12) (13) (14) (15) . Specifically, bufalin, either delivered alone or in the form of bufalin-loaded nanoparticles, kills breast cancer cells in vitro and inhibits breast cancer tumorigenesis in vivo (16, 17) . In addition, bufalin sensitizes breast cancer cells to TRAIL (18) (19) (20) . These cytotoxic and chemo-sensitizing effects of bufalin against breast cancer have been accredited to its ability to induce cancer cell apoptosis based on results from flow cytometric analysis (16, 17) . Considering that flow cytometry sometimes cannot adequately distinguish apoptotic cells from necrotic cells, we wondered whether necroptosis is involved in cancer cell death induced by bufalin. In the current study, we examined the form of cell death induced by bufalin in MCF-1 and MDA-MB-231 breast cancer cells. We found that bufalin kills breast cancer cells by triggering necroptosis through ROS-mediated RIP1/RIP3/ PARP-1 pathways.
Materials and methods

Reagents
Bufalin, dimethyl sulfoxide (DMSO), zVAD-fmk, Nec-1, NAC and DPQ were purchased from Sigma-Aldrich (St. Louis, MO). Anti-RIP1, anti-RIP3 and horseradish peroxidase-conjugated goat anti-rabbit IgG antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Anticleaved PARP and β-actin were obtained from Cell Signaling Technology (Beverly, MA).
Cell culture
The human breast cancer cell lines MCF-7 and MDA-MB-231 (obtained from the Cell Bank of the Shanghai Chinese Academy of Sciences in May 2015) were grown in RPMI 1640 and L15 medium (Gibco, Grand Island, NY), respectively, each supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin. Cell culture took place at 37°C, 5% CO 2 in a humidified incubator. Cells were passaged every 2-3 days and collected for use in experiments when they were in the logarithmic growth phase. In November 2016, the two cell lines used in this study were sent to Chinese Academy of Sciences and authenticated using Short Tandem Repeat Authentication.
Generation of stable cell lines
For RIP3 knockdown, a MISSION short-hairpin RNA (shRNA) targeting human RIP3 (shRIP3) or a MISSION non-targeting control shRNA (shRNA) (Sigma-Aldrich) were transfected into 293T cells (System Biosciences, CA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Pseudoviral particles were collected 48 h after the transduction. MCF-7 and MDA-MB-231 cells were infected with the pseudoviral particles in the presence of polybrene (8 μg/ml) and selected with puromycin for 48 h for stable shRNA expression. RIP3 knockdown was confirmed by immunoblotting.
For RIP3 overexpression, full-length human RIP3 cDNA was amplified from human genomic DNA by PCR using the following primers: forward, 5′-GGA ACT GGA GAA CCA GGA GC-3′; reverse, 5′-TCA GTC CTT CTA AGC CGG GA-3′. The PCR product was inserted into the lentiviral vector pCDH-CMV (System Biosciences). The lentiviral plasmids were subsequently purified and sequenced. The RIP3-expressing plasmids or empty control plasmids were transduced into 293T cells together with packaging vectors using Lipofectamine 2000. The rival supernatants were harvested 48 h after the transduction. MCF-7 and MDA-MB-231 cells were infected with the lentiviral medium for 48 h. RIP3 overexpression was confirmed by immunoblotting.
Cell treatment
Cells were seeded in 96-well plates (5 × 10 3 cells/well) and incubated at 37°C, 5% CO 2 for 24 h. After that, cells were treated with bufalin at indicated concentrations for indicated times with or without 45 min pretreatment with z-VAD-fmk, Nec-1, DPQ or NAC.
Cell viability assay
Cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. After treatment, cells were incubated with MTT (10 μl, 5 mg/ml) at 37°C for 2 h. The supernatant was removed and DMSO (100 μl) was added to solubilize the formazan crystals formed. The absorbance at 540 nm was recorded on a microplate reader (Bio-Rad Labs, Sunnyvale, CA).
Lactate dehydrogenase (LDH) release assay
LDH released into the culture medium was determined using a LDH assay kit (Roche Molecular Biochemicals, Mannheim, Germany) following manufacturer's instructions.
Annexin V-fluorescein/propidium iodide double staining assay
Loss of cell membrane integrity was assessed by the annexin V-fluorescein (FITC)/propidium iodide (PI) double staining assay (Vazyme Biotech, Nanjing, China). In brief, the cells were harvested and resuspended in 100 μl binding buffer containing 5 μl annexin V-FITC reagent and 5 μl PI reagent. After incubation for 15 min at room temperature in the dark, another 400 μl binding buffer was added, and the cells were subjected to analysis on a FACScan flow cytometer (Becton Dickinson). The excitation and emission wavelengths for annexin V-FITC detection were set at 488 and 525 nm, respectively, and PI were set at 575 and 615 nm. Data were analyzed with FlowJo software.
Determination of intracellular ROS
Intracellular ROS levels were determined using the cell-permeable fluorogenic probe 2ʹ, 7′-Dichlorodihydrofluorescin diacetate (DCFH-DA). Upon oxidation by ROS, the non-fluorescent DCFH-DA is converted to the highly fluorescent 2′, 7′-dichlorofluorescein (DCF), which can be detected by flow cytometry. In brief, the cells were harvested, incubated with 50 µM DCFH-DA at 37°C in the dark for 10 min, and subjected to analysis on a FACScan flow cytometer (Becton Dickinson). The excitation and emission wavelengths were set at 488 and 525 nm, respectively, for the detection of DCF.
Western blot analysis
Total protein was extracted using the M-PER® Mammalian Protein Extraction Reagent (ThermoFisher Scientific). Protein concentrations were determined using the Bradford method. Samples (20 μg each) were separated by 10% SDS-PAGE and transferred to PVDF membranes (Millipore, Bedford, MA). After blocking with 5% milk in TBS containing Tween 20 (TBS-T) for 30 min, the membranes were incubated with antibodies toward RIP1, RIP3, cleaved PARP-1 and β-actin, respectively, at 4°C overnight. After washing, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies at room temperature for 1 h. Protein bands were visualized by chemiluminescent detection and the densitometric values were determined using a gel image analysis system (Bio-Rad, Hercules, CA). Data were normalized to β-actin.
Tumor xenograft study
MDA-MB-231 cells (1 × 10 6 ) in 50 μl of phosphate-buffered saline and 50 μl of Matrigel matrix (BD Biosciences) were orthotopically injected into the mammary fat pads of BALB/c nude female mice (6-week-old; Shanghai Laboratory Animal Center, Shanghai, China) to induce tumor formation. After the tumors grew over 100 mm 3 , the mice received intraperitoneal injection of bufalin (1 mg/kg), DPQ (5 mg/kg), or 100 μl isotonic solution (control), alone or in combination every 3 days for 3 weeks. Tumor volumes were estimated using the following formula: V = 1/2 * a * b 2 , where a and b represents the largest and shortest perpendicular axis, respectively. At the end of treatment, the mice were sacrificed by cervical dislocation. The tumors were harvested and tumor weights were recorded. All experiments were performed in accordance with the Chinese legislation on the use and care of laboratory animals and were approved by the Animal Care and Use Committee of the first affiliated hospital of China Medical University.
Haematoxylin and eosin staining
Tumor tissues were fixed in 4% paraformaldehyde, embedded in pure paraffin and cut into 4-μm sections. The paraffin sections were affixed to glass slides, deparaffinised in xylene, rehydrated and stained with haematoxylin and eosin. The slides were subsequently dehydrated in a graded series of ethanol solutions, cleared in xylene, cemented with neutral resin and examined under a light microscope (Olympus Optical, Tokyo, Japan).
TUNEL staining
The terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining labels DNA strand breaks generated during cell death. TUNEL staining of tumor tissues was performed using a TUNEL reagent kit (Roche) following manufacturer's instructions. by the LDH release assay. n = 3, *P < 0.05, **P < 0.01.
Statistical analysis
All results are presented in mean ± SD. Data were analyzed using GraphPad Prism 5 software (GraphPad, San Diego, CA). Results from two treatment groups were compared using two-tailed Student's t-test. Differences with a P value < 0.05 were considered statistically significant.
Results
Bufalin induces caspase-independent cell death in human breast cancer cells
We first tested the effects of bufalin on cell viability of human breast cancer cells using the MTT assay. As shown in Figure 1A , bufalin elicited a decrease in cell viability in a dose-and timedependent manner in MCF-7 and MDA-MB-231 breast cancer cells. To our surprise, pretreatment with the pan-caspase inhibitor zVAD-fmk had no effects on bufalin-induced cytotoxicity ( Figure 1B) . To further characterize bufalin-induced cell death, we examined loss of cell membrane integrity by the LDH release assay. Pretreatment with zVAD-fmk failed to inhibit bufalininduced LDH release ( Figure 1C) , confirming that the cell death induced by bufalin is caspase-independent.
Bufalin induces necroptosis in human breast cancer cells through the RIP1/RIP3/PARP-1 pathways
To find out whether the caspase-independent breast cancer cell death by bufalin is associated with necroptosis, we examined the protein levels of the necroptosis mediators RIP1 and RIP3 by western blot analysis. RIP1 was detected in both MCF-7 and MDA-MB-231 cells (Figure 2A ). We detected low RIP3 expression in MDA-MB-231 cells while the RIP3 signal in MCF-7 cells was too weak to be detected. Bufalin increased RIP1 expression in both MCF-7 and MDA-MB-231 cells in a dose-dependent manner. Bufalin also markedly increased RIP3 expression in MDA-MB-231 cells; however, it showed little effects on RIP3 in MCF-7 cells that were RIP3-deficient (Figure 2A) . The cytotoxic effects of bufalin on both MCF-7 and MDA-MB-231 cells measured by MTT and LDH release were prevented by pretreatment with the RIP1 inhibitor Nec-1 ( Figure 2B and C) . Disruption of internal and external membranes is not only associated with apoptosis, but also a normal consequence of necrosis. To further verify the form of death by bufalin and the involvement of RIP1, we assessed cell membrane integrity using annexin V-FITC/PI double staining. The readout was demonstrated to be appropriate for evaluation of necroptosis in the presence of Nec-1 (21, 22) . Treatments modulate PI uptake with minimal modification of annexin V binding, indicative of necrotic instead of apoptotic type of cell death. The data revealed increased percentage of necrotic cells following bufalin treatment ( Figure 2D ). This increase in necrotic cells by bufalin was prevented by pretreatment with Nec-1 in MCF-7 and MDA-MB-231 cells ( Figure 2D ). These data provided further and strong evidence that bufalin provoked necrosis in MCF-7 and MDA-MB-231 cells via RIP1-dependent pathway.
To test the involvement of RIP3, we modified RIP3 expression using a RIP3-targeting shRNA (shRIP3). In MDA-MB-231 cells that showed endogenous RIP3 expression, shRIP3 transfection effectively reduced RIP3 expression and prevented bufalin-induced cell death. In MCF-7 cells that showed exceptionally low RIP3 expression, shRIP3 transfection had no significant effects on bufalin-induced cell death ( Figure 3A-C) . However, ectopic RIP3 expression bestowed additional sensitivity to bufalin in both MDA-MB-231 and MCF-7 cells as measured by multiple assays (Figure 3D-F) . Together, these data supported the involvement of RIP3 in cell death by bufalin. The failure to prevent bufalininduced cell death by shRIP3 transfection in MCF-7 could be attributed to ineffective suppression of RIP3, which was already expressed at a very low level in this cell line. PARP-1 has been reported to be a downstream effector of RIP1/RIP3 in TRAIL-induced necroptosis (5) . In this study, we found that bufalin increased the level of cleaved PARP-1, and shRIP3 transfection reduced cleaved PARP-1 level increased by bufalin in both MCF-1 and MDA-MB-231 cells ( Figure 3G ). In addition, bufalin-induced PARP-1 expression and cell death in both MCF-1 and MDA-MB-231 cells were inhibited by the specific PARP-1 inhibitor DPQ (Figure 3H-J) . Thus, the PARP-1 pathway is involved in bufalin-induced necroptosis.
Bufalin induces breast cancer cell death via ROS generation
Uncontrolled reactive oxygen species (ROS) production can trigger necrosis in cancer cells (23, 24) . Because bufalin has been reported to increase ROS levels in breast cancer cells (16), we speculated that ROS production may be a mediator of bufalin-induced cell death in MCF-7 and MDA-MB-231 cells. To test this, we determined intracellular ROS levels by flow cytometry using DCFH-DA staining. Indeed, increased ROS levels were detected following bufalin treatment, and bufalin-induced ROS generation was prevented by pretreatment with the RIP1 inhibitor Nec-1 ( Figure 4A ), suggesting that ROS acts downstream of RIP1. Western blotting analysis revealed that inhibition of ROS with the antioxidant N-acetyl-cysteine (NAC) attenuated bufalin-induced upregulation of cleaved PARP-1 ( Figure 4B ). Concomitantly, bufalin-induced cell death was obviously prevented after the abnormal ROS level was mitigated by NAC ( Figure 4D and E). ShRIP3 transfection blocked bufalin-induced ROS generation in MAD-MB-231 but not RIP3-deficient MCF-1 cells ( Figure 4F) ; however, NAC inhibited bufalininduced cell death enhanced by ectopic RIP3 expression in both MAD-MB-231 and MCF-1 cells ( Figure 4G ). Thus, ROS appears to act downstream of RIP1/RIP3 and upstream of PARP-1 in the necroptotic cascade activated by bufalin. Interestingly, NAC also suppressed RIP1 induction by bufalin (Figure 4C) , signaling a feedforward regulation of RIP1 by ROS.
Bufalin inhibits breast cancer tumorigenesis in vivo by inducing necrosis
To find out whether our in vitro findings apply to breast cancer tumorigenesis in vivo, we established a mouse xenograft model of human breast cancer using MAD-MB-231 cells. Intraperitoneal injection of bufalin (1 mg/kg) once every 3 days for 3 weeks significantly inhibited tumor growth as measured in tumor volume and tumor weight ( Figure 5A and B) . The PARP-1 inhibitor DPQ, while showing no effects when used alone, restored tumor growth inhibited by bufalin when it was co-injected with bufalin. Haematoxylin and eosin staining of tumor tissues revealed that the tumor cell density was reduced and less stained in the bufalin-treated group compared with the control group. Furthermore, areas of necrosis were noted by TUNEL staining in the bufalin-treated group, and were reversed by co-administration of DPQ ( Figure 5C ).
Discussion
Resistance to caspase-dependent apoptosis has become a major obstacle in cancer treatment. Necroptosis is a form of programmed cell death, and a major pathway of cell death when apoptosis is suppressed or absent (25) . A necroptotic process ultimately leads to rupture of the cell membrane and subsequent release of damage-associated molecular patterns (DAMPs) that activate immune responses (26) . The ability of necroptosis to kill cancer cells combined with its potential to recruit and activate immune cells at the tumor site make it an attractive new anticancer mechanism to combat apoptosis resistance (7) . Several strategies to harness necroptosis for cancer treatment are currently under preclinical and clinical investigation, and early results from these studies look promising (7) .
Although bufalin has been demonstrated to kill cancer cells, the signaling pathways underlying bufalin-induced cell death have not been elucidated. In this study, we found evidence that bufalin-induced cell death in breast cancer cells mainly by inducing ROS-mediated, RIP1/RIP3/PARP-1-dependent necroptosis. The caspase inhibitor zVAD-fmk failed to block breast cancer cell death by bufalin, indicating that bufalin-induced cell death is via caspase-independent mechanism. Bufalin induced the necroptosis mediators RIP1, RIP3 and cleaved PARP-1. Inhibition of RIP1 or PARP-1 by small molecule inhibitors or genetic knockdown of RIP3 by shRNA prevented bufalin-induced cell death. In addition, ectopic RIP3 expression sensitized breast cancer cells to bufalin. Bufalin increased intracellular ROS levels; and cell death by bufalin was inhibited by the antioxidant NAC. Furthermore, in a mouse xenograft model of breast cancer, bufalin induced PARP-1-dependent tumor cell necrosis and inhibited tumor growth.
Bufalin was thought to kill breast cancer cells by inducing apoptosis in a number of previous reports (27, 28) . In these studies, 'apoptosis' was assessed by flow cytometry using annexin V-FITC staining for membrane disintegration and/or PI staining after cell fixation for presence of hypodiploid DNA. However, necrotic cells can also display membrane abnormalities as well as DNA degradation that may result in hypodiploid nuclei. In this study, we used chemical as well as genetic modulation of apoptosis and necroptosis mediators to characterize bufalininduced cell death of breast cancer cells. Our in vitro studies provided the proof for necroptotic cell death by bufalin, and this was confirmed by morphohistological examination on tumor tissues in our in vivo xenograft study. The two most studied models of necroptosis are the TNFinduced, RIP1/RIP3-dependent necroptosis and the PARPmediated necroptosis. The first is initiated by TNF receptor activation and subsequent recruitment of the TNF receptorassociated death domain (TRADD), which then recruits RIP1. In the absence of caspase 8 activity, RIP1 and RIP3 can auto-and transphosphorylate each other to form a complex called necrosome. The necrosome then activates pronecrotic kinase activity and triggers downstream ROS production, eventually leading to necrotic cell death (29, 30) . The PARP-mediated necroptosis is initiated by overactivation of the DNA repair enzyme PARP-1 in response to extrinsic stimulus, such as a DNA-alkylating agent, causing caspase-independent, extensive DNA fragmentation and eventually, necrosis (31) . The PARP pathway has also been implicated as an integral part of TNF-induced necroptosis in fibrosarcoma cells (32) . Our data suggest that both the RIP1/RIP3 and PARP-1 pathways are involved in bufalin-induced necroptosis in breast cancer cells. Inhibition of RIP1 and PARP-1 by small molecule inhibitors and downregulation of RIP3 by shRIP3 transfection abrogated bufalin-induced necroptosis in MDA-MB-231 cells. In MCF-7 cells that express exceptionally low level of RIP3, inhibition of RIP1 and PARP-1 but not shRIP3 transfection, reduced bufalin-induced necroptosis. Nonetheless, ectopic RIP3 expression in MCF-7 enhanced bufalin-induced necroptosis, supporting the RIP1/RIP3 pathway as a pronecroptotic mechanism in these cells, albeit a possibly less significant one compared with PARP-1. The failure to inhibit necroptosis by shRIP3 transfection in MCF-7 could be attributed to ineffective suppression of RIP3, which was already expressed at a very low level in these cells.
During chemotherapy, drug resistance frequently develops in breast cancer patients, which may lead to treatment failure (33) . RIP3 expression is downregulated in 85% of breast cancer patients (8) ; thus, deficiency in necroptosis may contribute to drug resistance. We believe that breast cancer patients may benefit from treatment with necroptosis-inducing agents like bufalin in combination with overexpression of RIP3. Future preclinical and clinical studies are required to verify this strategy.
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